Applied Filters
Lundbeck loses €150m pay-for-delay appeal
Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.
UK implored to back COVID-19 IP waiver at WTO
The UK has been urged to back a proposed IP waiver related to COVID-19 treatments before the World Trade Organisation by business leaders, academics, economists and trade unions.
Five minutes with… Penny Gilbert
The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.
AstraZeneca to buy Alexion for $39bn
AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.
Danish university sues Creative Biolabs over ‘antibody pirating’
The University of Southern Denmark has accused biotech Creative Biolabs of infringing its patent-protected monoclonal antibody, HG-HYB 7-5.
MSF urges EU to rid market of ‘avoidable suffering’ from SPCs
Médecins Sans Frontières has warned that the European Commission’s commitment to the supplementary protection certificate system risks undermining its promise to improve drug accessibility.
EC fines Teva €60.5m over pay-for-delay deal
The European Commission has fined Teva and its subsidiary Cephalon €60.5 million for agreeing to delay a cheaper generic version of sleep disorder drug modafinil.
Emer Cooke becomes first woman to lead EMA
The first woman to act as executive director of the European Medicines Agency (EMA) has officially started in the role.
UKIPO rejects BASF’s agri-chemical trademark opposition
German chemicals company BASF has failed to persuade the UK Intellectual Property Office that an applied-for trademark to cover agricultural chemicals is confusingly similar to its own existing trademark.
EC signs contract with Pfizer to access watershed vaccine
The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.
